MeSH tree: D03.383.903.075
A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of type 2 diabetes mellitus (T2DM) in children and adolescents.
Aug 4, 2025
0
17
Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention. An Osaka Metropolitan University-led research group has investigated ...
Nov 18, 2024
0
21
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.
Oct 25, 2024
0
19
Aging-related physiological decline and the accumulation of senescent or aging cells in bodily tissues can trigger a number of diseases. The removal of senescent cells, also known as "senolysis," can therefore serve as an ...
May 30, 2024
0
60
A simple blood test may predict the risk of progressive heart and kidney disease in people with type 2 diabetes and kidney disease, according to new research published in the journal Circulation.
Aug 21, 2023
0
60
Wearable devices like smartwatches continually track physical activity, urging folks to take more daily steps for their health.
Jul 30, 2023
0
44
Swansea University researchers have found that a drug commonly used to treat type 2 diabetes can potentially be used in the treatment of autoimmune disorders.
May 25, 2023
0
86
A large-scale new study offers a new approach to treating in type 2 diabetes, one that puts patients in charge of their own medication. The Trimaster study is the first to allow people with type 2 diabetes to choose their ...
Dec 7, 2022
0
80
